Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy

Current Treatment Options in Allergy

Volumn 1, Issue 1, 2014, Pages 91-106

  Marth, Katharina ^a   Focke Tejkl, Margarete ^a   Lupinek, Christian ^a   Valenta, Rudolf ^a   Niederberger, Verena ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen; Allergy; Clinical efficacy; Diagnosis; Hypoallergens; IgE; Recombinant allergen; Symptoms; Treatment; Vaccines

Indexed keywords

EID: 84909579004     PISSN: None     EISSN: 21963053     Source Type: Journal    
DOI: 10.1007/s40521-013-0006-5     Document Type: Review

References (107)

1. Kay AB. Allergy and allergic diseases. Oxford: Edited by Blackwell Publishing Ltd.; 2008. DOI: 10.1002/9781444300918
2. van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol. 1999;163:2944–52.
3. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999;189:1885–94. DOI: 10.1084/jem.189.12.1885
4. Purohit A, Niederberger V, Kronqvist M, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy. 2008;38:1514–25. DOI: 10.1111/j.1365-2222.2008.03042.x
5. Campana R, Mothes N, Rauter I, et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol. 2008;121:528–30. DOI: 10.1016/j.jaci.2007.09.014
6. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–75. DOI: 10.1056/NEJM199908123410702
7. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288–96. DOI: 10.1016/j.jaci.2013.01.049
8. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–6. DOI: 10.1067/mai.2002.121317
9. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–8. DOI: 10.1111/j.1398-9995.2007.01451.x
10. Focke M, Marth K, Flicker S, et al. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy. 2008;38:1400–8. DOI: 10.1111/j.1365-2222.2008.03031.x
11. Focke M, Marth K, Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest. 2009;39:429–36. DOI: 10.1111/j.1365-2362.2009.02109.x
12. Brunetto B, Tinghino R, Braschi MC, et al. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy. 2010;65:184–90. DOI: 10.1111/j.1398-9995.2009.02150.x
13. Curin M, Reininger R, Swoboda I, et al. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol. 2011;154:258–63. DOI: 10.1159/000321113
14. Casset A, Valenta R, Vrtala S. Allergen content and in vivo allergenic activity of house dust mite extracts. Int Arch Allergy Immunol. 2013;161:287–8. Demonstrates the varying composition of house dust mite allergen extracts. DOI: 10.1159/000347047
15. Valenta R, Ferreira F, Focke-Tejkl M, et al. From allergen genes to allergy vaccines. Annu Rev Immunol. 2010;28:211–41. DOI: 10.1146/annurev-immunol-030409-101218
16. van Ree R, Chapman MD, Ferreira F, et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy. 2008;63:310–26. DOI: 10.1111/j.1398-9995.2007.01612.x
17. Valenta R, Steinberger P, Duchene M, et al. Immunological and structural similarities among allergens: prerequisite for a specific and component-based therapy of allergy. Immunol Cell Biol. 1996;74:187–94. DOI: 10.1038/icb.1996.26
18. Mothes N, Horak F, Valenta R. Transition from a botanical to a molecular classification in tree pollen allergy: implications for diagnosis and therapy. Int Arch Allergy Immunol. 2004;135:357–73. DOI: 10.1159/000082332
19. Radauer C, Bublin M, Wagner S, et al. Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J Allergy Clin Immunol. 2008;121:847–52. DOI: 10.1016/j.jaci.2008.01.025
20. Hoffmann-Sommergruber K, Mills EN. Food allergen protein families and their structural characteristics and application in component-resolved diagnosis: new data from the EuroPrevall project. Anal Bioanal Chem. 2009;395:25–35. DOI: 10.1007/s00216-009-2953-z
21. Weber RW. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99:203–11. DOI: 10.1016/S1081-1206(10)60654-0
22. Cromwell O, Hafner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol. 2011;127:865–72. DOI: 10.1016/j.jaci.2011.01.047
23. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–13. DOI: 10.1016/j.jaci.2005.06.004
24. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122:951–60. DOI: 10.1016/j.jaci.2008.09.017
25. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101:14677–82. DOI: 10.1073/pnas.0404735101
26. Niederberger V, Valenta R. Molecular approaches for new vaccines against allergy. Expert Rev Vaccines. 2006;5:103–10. DOI: 10.1586/14760584.5.1.103
27. Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012;30:4328–35. DOI: 10.1016/j.vaccine.2011.11.011
28. Chen KW, Blatt K, Thomas WR, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol. 2012;130:435–43.
29. Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol. 2004;134:324–31. DOI: 10.1159/000079535
30. Linhart B, Hartl A, Jahn-Schmid B, et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol. 2005;115:1010–6. DOI: 10.1016/j.jaci.2004.12.1142
31. Larche M. T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol. 2011;352:107–19.
32. Norman PS, Ohman Jr JL, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623–8. DOI: 10.1164/ajrccm.154.6.8970345
33. Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO - ARIA - GA(2)LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6:17. Important position paper regarding molecular allergy diagnosis. DOI: 10.1186/1939-4551-6-17
34. van der Veen MJ, Mulder M, Witteman AM, et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol. 1996;98:1028–34. DOI: 10.1016/S0091-6749(96)80187-4
35. Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol. 2003;111:777–83. DOI: 10.1067/mai.2003.1338
36. Valerio CR, Murray P, Arlian LG, et al. Bacterial 16S ribosomal DNA in house dust mite cultures. J Allergy Clin Immunol. 2005;116:1296–300. DOI: 10.1016/j.jaci.2005.09.046
37. Winther LPL, Robin B, Mélac M, Malling H. Safety and tolerability of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT). J Allergy Clin Immunol. 2009;123:215. DOI: 10.1016/j.jaci.2008.12.822
38. Grönlund H, Gafvelin G. Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen. Hum. Vaccin. 2010;6:970–7.
39. Reisinger J, Horak F, Pauli G, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005;116:347–54. DOI: 10.1016/j.jaci.2005.04.003
40. Pree I, Reisinger J, Focke M, et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol. 2007;179:5309–16.
41. Klimek L, Mewes T, Wolf H, et al. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity. Otolaryngol Head Neck Surg. 2005;133:538–43. DOI: 10.1016/j.otohns.2005.07.020
42. Kahlert H, Suck R, Weber B, et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2008;145:193–206. DOI: 10.1159/000109288
43. Meyer W, Narkus A, Salapatek AM, et al. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy. 2013;68:724–31. DOI: 10.1111/all.12148
44. Haselden BM, Larche M, Meng Q, et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol. 2001;108:394–401. DOI: 10.1067/mai.2001.117460
45. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127:89–97. Important clinical study regarding T cell peptide-based immunotherapy. DOI: 10.1016/j.jaci.2010.11.029
46. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–9. DOI: 10.1016/j.jaci.2012.07.028
47. Muller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101:747–54. DOI: 10.1016/S0091-6749(98)70402-6
48. Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol. 2003;111:854–61. DOI: 10.1067/mai.2003.1337
49. Pellaton C, Perrin Y, Boudousquie C, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy. 2013;3:17. DOI: 10.1186/2045-7022-3-17
50. Vrtala S, Hirtenlehner K, Vangelista L, et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest. 1997;99:1673–81. DOI: 10.1172/JCI119330
51. Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 2012;12:555–63. DOI: 10.1097/ACI.0b013e328357ca53
52. Focke M, Mahler V, Ball T, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 2001;15:2042–4.
53. Focke-Tejkl M, Campana R, Reininger R, et al. Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. J Allergy Clin Immunol 2013. doi: 10.1016/j.jaci.2013.08.038.Demonstration that IgE and T cell recognition of the major group 5 allergen from timothy grass pollen can be dissected for the development of SIT strategies targeting T cells or B cells.
54. Focke M, Linhart B, Hartl A, et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy. 2004;34:1525–33. DOI: 10.1111/j.1365-2222.2004.02081.x
55. Twaroch TE, Focke M, Civaj V, et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol. 2011;128:178–84. DOI: 10.1016/j.jaci.2011.03.011
56. Twaroch TE, Focke M, Fleischmann K, et al. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy. 2012;42:966–75.
57. Edlmayr J, Niespodziana K, Focke-Tejkl M, et al. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases. Curr Top Microbiol Immunol. 2011;352:121–40.
58. Edlmayr J, Niespodziana K, Linhart B, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol. 2009;182:6298–306. DOI: 10.4049/jimmunol.0713622
59. Marth K, Breyer I, Focke-Tejkl M, et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol. 2013;190:3068–78. Preclinical characterization of a safe vaccine for birch pollen allergy. DOI: 10.4049/jimmunol.1202441
60. Niespodziana K, Focke-Tejkl M, Linhart B, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. 2011;127:1562–70. DOI: 10.1016/j.jaci.2011.02.004
61. Nilsson OB, Adedoyin J, Rhyner C, et al. In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One. 2011;6:e24558. DOI: 10.1371/journal.pone.0024558
62. Tourdot S, Airouche S, Berjont N, et al. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. Vaccine. 2013;31:2628–37. DOI: 10.1016/j.vaccine.2013.03.041
63. Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: the present and the future. Hum Vaccin Immunother. 2012;8:1534–43. DOI: 10.4161/hv.22064
64. Suzuki K, Kaminuma O, Yang L, et al. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotechnol J. 2011;9:982–90. DOI: 10.1111/j.1467-7652.2011.00613.x
65. Takagi H, Hiroi T, Yang L, et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for ihibition of Th2-mediated IgE responses. Proc Natl Acad Sci U S A. 2005;102:17525–30.
66. Hiroi T, Kaminuma O, Takaiwa F. Vaccination with transgenic rice seed expressing mite allergen: a new option for asthma sufferers? Expert Rev Vaccines. 2011;10:1249–51. DOI: 10.1586/erv.11.102
67. Yang L, Hirose S, Suzuki K, et al. Expression of hypoallergenic Der f 2 derivatives with altered intramolecular disulphide bonds induces the formation of novel ER-derived protein bodies in transgenic rice seeds. J Exp Bot. 2012;63:2947–59. DOI: 10.1093/jxb/ers006
68. Wang S, Takahashi H, Kajiura H, et al. Transgenic rice seeds accumulating recombinant hypoallergenic birch pollen allergen Bet v 1 generate giant protein bodies. Plant Cell Physiol. 2013;54:917–33. DOI: 10.1093/pcp/pct043
69. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–6. Intralymphatic immunotherapy study carried out with a recombinant allergen derivative. DOI: 10.1016/j.jaci.2012.02.026
70. Wood RA, Sicherer SH, Burks AW, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68:803–8. DOI: 10.1111/all.12158
71. Gafvelin G, Thunberg S, Kronqvist M, et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol. 2005;138:59–66. DOI: 10.1159/000087358
72. Klimek L, Bachert C, Doemer C, et al. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin Immunol Int. 2005, Suppl. No 1:15.
73. Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360:47–53. DOI: 10.1016/S0140-6736(02)09332-7
74. Edlmayr J, Niespodziana K, Popow-Kraupp T, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J. 2011;37:44–52. DOI: 10.1183/09031936.00149109
75. Focke M, Swoboda I, Marth K, et al. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40:385–97. DOI: 10.1111/j.1365-2222.2009.03443.x
76. Rancitelli P, Hofmann A, Burks AW. Vaccine approaches for food allergy. Curr Top Microbiol Immunol. 2011;352:55–69.
77. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654–60. DOI: 10.1016/j.jaci.2010.12.1111
78. Takaiwa F. Seed-based oral vaccines as allergen-specific immunotherapies. Hum Vaccin. 2011;7:357–66. DOI: 10.4161/hv.7.3.14302
79. Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186:5629–37. DOI: 10.4049/jimmunol.1003134
80. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002. DOI: 10.1016/j.jaci.2009.07.019
81. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129:128–35. DOI: 10.1016/j.jaci.2011.08.036
82. Mondoulet L, Dioszeghy V, Vanoirbeek JA, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol. 2011;154:299–309. DOI: 10.1159/000321822
83. Hessenberger M, Weiss R, Weinberger EE, et al. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores. Vaccine. 2013;31:3427–34. DOI: 10.1016/j.vaccine.2012.09.086
84. Hylander T, Latif L, Petersson-Westin U, et al. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013;131:412–20. DOI: 10.1016/j.jaci.2012.10.056
85. Meechan P, Tungtrongchitr A, Chaisri U, et al. Intranasal, liposome-adjuvanted cockroach allergy vaccines made of refined major allergen and whole-body extract of Periplaneta americana. Int Arch Allergy Immunol. 2013;161:351–62. doi:10.1159/000348314.
86. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–71. DOI: 10.1038/nri1934
87. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol. 2003;132:13–24. DOI: 10.1159/000073260
88. Valenta R, Lidholm J, Niederberger V, et al. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999;29:896–904. DOI: 10.1046/j.1365-2222.1999.00653.x
89. Kazemi-Shirazi L, Niederberger V, Linhart B, et al. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol. 2002;127:259–68. DOI: 10.1159/000057742
90. Hiller R, Laffer S, Harwanegg C, et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 2002;16:414–6.
91. Lupinek C, Wollmann E, Baar A, et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods 2013, in press.Characterization and important technical features of an allergen microarray suitable for analyzing early IgE responses in birth cohorts and children.
92. Harwanegg C, Laffer S, Hiller R, et al. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy. 2003;33:7–13. DOI: 10.1046/j.1365-2222.2003.01550.x
93. Zimmer A, Bouley J, Le Mignon M, et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J Allergy Clin Immunol. 2012;129:1020–30. DOI: 10.1016/j.jaci.2012.02.014
94. Selb R, Eckl-Dorna J, Vrtala S, et al. An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy. Allergy. 2013;68:1199–202.
95. Zitnik SE, Vesel T, Avcin T, et al. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr Allergy Immunol. 2012;23:166–72. DOI: 10.1111/j.1399-3038.2011.01233.x
96. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006;317:71–9. DOI: 10.1016/j.jim.2006.09.004
97. Gödicke V, Hundt F. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. Allergy. 2010;65:1499–505. DOI: 10.1111/j.1398-9995.2010.02436.x
98. Moverare R, Elfman L, Vesterinen E, et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002;57:423–30. DOI: 10.1034/j.1398-9995.2002.13248.x
99. Valenta R, Campana R, Marth K, et al. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med. 2012;272:144–57. Summary of considerations for allergen-specific prophylactic approaches. DOI: 10.1111/j.1365-2796.2012.02556.x
100. Bousquet J, Anto J, Sunyer J, et al. Pooling birth cohorts in allergy and asthma: European Union-funded initiatives - a MeDALL, CHICOS, ENRIECO, and GA(2)LEN joint paper. Int Arch Allergy Immunol. 2013;161:1–10. DOI: 10.1159/000343018
101. Kulig M, Bergmann R, Klettke U, et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol. 1999;103:1173–9. DOI: 10.1016/S0091-6749(99)70195-8
102. Lupinek C, Marth K, Niederberger V, et al. Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults. J Allergy Clin Immunol. 2012;130:1418–20. DOI: 10.1016/j.jaci.2012.06.028
103. Uthoff H, Spenner A, Reckelkamm W, et al. Critical role of preconceptional immunization for protective and nonpathological specific immunity in murine neonates. J Immunol. 2003;171:3485–92.
104. Hansen JS, Nygaard UC, Lyle R, et al. Early life interventions to prevent allergy in the offspring: the role of maternal immunization and postnatal mucosal allergen exposure. Int Arch Allergy Immunol. 2012;158:261–75. doi:10.1159/000332963.
105. Flicker S, Marth K, Kofler H, et al. Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy-treated mother. J Allergy Clin Immunol. 2009;124:1358–60. DOI: 10.1016/j.jaci.2009.09.024
106. Glovsky MM, Ghekiere L, Rejzek E. Effect of maternal immunotherapy on immediate skin test reactivity, specific rye I IgG and IgE antibody, and total IgE of the children. Ann Allergy. 1991;67:21–4.
107. Cabauatan CR, Lupinek C, Scheiblhofer S, et al. Allergen microarray detects high prevalence of asymptomatic IgE sensitizations to tropical pollen-derived carbohydrates. J Allergy Clin Immunol 2013, in press.Allergen-microarray revealing an unexpected allergen recognition profile in the Asian Pacific area.